[3-(3-hydroxy-4-methoxyphenyl)-4-methoxy-1H-indol-2-yl]-(3,4,5-trimethoxyphenyl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [3-(3-hydroxy-4-methoxyphenyl)-4-methoxy-1H-indol-2-yl]-(3,4,5-trimethoxyphenyl)methanone
• 化学式: C₂₆H₂₅NO₇
• 分子量: 463.5
• InChiKey: GNVZIVLPENPHJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  99.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
  申请人：Pinney G. Kevin

  公开号：US20050065217A1

  公开（公告）日：2005-03-24

  Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting and destruction chemotherapeutic agents or to have anti-angiogenesis activity resulting in the selective prevention and/or destruction of tumor cell vasculature.

  已经发现了替甲氧苯基取代的吲哚配体，它们展示出令人印象深刻的细胞毒性以及抑制微管聚合的显着能力。这些化合物以及相关衍生物是治疗人类癌症的优秀临床候选药物。此外，其中某些配体作为前药，可能被证明是肿瘤选择性靶向血管破坏化学治疗药物，或具有抗血管生成活性，从而选择性地预防和/或破坏肿瘤细胞血管。
• INDOLE-CONTAINING AND COMBRETASTATIN-RELATED ANTI-MITOTIC AND ANTI-TUBULIN POLYMERIZATION AGENTS
  申请人：BAYLOR UNIVERSITY

  公开号：EP1214298A2

  公开（公告）日：2002-06-19
• US6849656B1
  申请人：——

  公开号：US6849656B1

  公开（公告）日：2005-02-01
• [EN] INDOLE-CONTAINING AND COMBRETASTATIN-RELATED ANTI-MITOTIC AND ANTI-TUBULIN POLYMERIZATION AGENTS<br/>[FR] AGENTS DE POLYMERISATION ANTIMITOTIQUES ET ANTITUBULINES CONTENANT DE L'INDOLE ET APPARENTES A LA COMBRETASTATINE
  申请人：UNIV BAYLOR

  公开号：WO2001019794A2

  公开（公告）日：2001-03-22

  Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting and destruction chemotherapeutic agents or to have anti-angiogenesis activity resulting in the selective prevention and/or destruction of tumor cell vasculature.